330 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
330 FAQ
What was PhaseRx Inc’s price range in the past 12 months?
Currently, no data Available
What is PhaseRx Inc’s market cap?
PhaseRx Inc’s market cap is €11.00.
When is PhaseRx Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PhaseRx Inc’s earnings last quarter?
Currently, no data Available
Is PhaseRx Inc overvalued?
According to Wall Street analysts PhaseRx Inc’s price is currently Undervalued.
Does PhaseRx Inc pay dividends?
PhaseRx Inc does not currently pay dividends.
What is PhaseRx Inc’s EPS estimate?
PhaseRx Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PhaseRx Inc have?
Currently, no data Available
What happened to PhaseRx Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PhaseRx Inc?
Currently, no hedge funds are holding shares in DE:330
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PhaseRx Inc
PhaseRx, Inc. is a biopharmaceutical company dedicated to developing treatments for inherited enzyme deficiencies affecting the liver. Its therapeutic strategy involves intracellular enzyme replacement, powered by its unique Hybrid mRNA technology platform, which facilitates the production of absent enzymes directly within the body's cells. The company's pipeline includes several programs targeting urea cycle disorders, such as PRX-OTC for ornithine transcarbamylase deficiency, PRX-ASL for argininosuccinate lyase deficiency, and PRX-ASS1 for argininosuccinate synthetase deficiency. Established in 2006, PhaseRx is headquartered in Seattle, Washington.
―
Scinai Immunotherapeutics
―
PainReform
―
Dermata Therapeutics
―
Virax Biolabs Group Ltd. Class A
―